These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102. Secondary Acute Myeloid Leukemia in a Chronic Myeloid Leukemia Patient in Deep Molecular Response-An Unusual Case Report. Bharathi Devi G; Jayachandran PK; Arumugam JR; Bommannan K; Sundersingh S South Asian J Cancer; 2022 Apr; 11(2):175-177. PubMed ID: 36466981 [TBL] [Abstract][Full Text] [Related]
103. Chloroquine Intervenes Nephrotoxicity of Nilotinib through Deubiquitinase USP13-Mediated Stabilization of Bcl-XL. Yan H; Huang X; Xu J; Zhang Y; Chen J; Xu Z; Li H; Wang Z; Yang X; Yang B; He Q; Luo P Adv Sci (Weinh); 2023 Sep; 10(26):e2302002. PubMed ID: 37452432 [TBL] [Abstract][Full Text] [Related]
104. Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report. Huang SM; Tao T; Wan CL; Wu TM; Cao HY; Qiu Y; Shen XD; Wang BR; Ge SS; Li YY; Zhang TT; Wu B; Xue SL Clin Case Rep; 2023 Jan; 11(1):e6688. PubMed ID: 36619491 [TBL] [Abstract][Full Text] [Related]
105. Prevalence of atypical BCR-ABL1 transcript types in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: implications for measurable residual disease. Bhreathnach Ú; Kearney L; Langabeer SE Hematol Transfus Cell Ther; 2022; 44(1):130-131. PubMed ID: 34284978 [No Abstract] [Full Text] [Related]
106. BCR::ABL1 fusion gene positive de novo acute myeloid leukemia with coexistence of NRAS mutation and presented with a peculiar CD58 positive immunophenotype. Zhang X; Guo X Cytometry B Clin Cytom; 2024 Mar; 106(2):146-148. PubMed ID: 37969054 [No Abstract] [Full Text] [Related]
107. Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies. Kopmar NE; Othus M; Gardner KM; Shaw C; Halpern AB; Scott BL; Hendrie PC; Walter RB; Becker PS; Estey EH; Percival MM Leukemia; 2022 Apr; 36(4):1164-1166. PubMed ID: 35058596 [No Abstract] [Full Text] [Related]
108. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Zhou T; Curry CV; Khanlari M; Shi M; Cui W; Peker D; Chen W; Wang E; Gao J; Shen Q; Xie W; Jelloul FZ; King RL; Yuan J; Wang X; Zhao C; Obiorah IE; Courville EL; Nomura E; Cherian S; Xu ML; Burack WR; Liu HX; Jabbour EJ; Takahashi K; Wang W; Wang SA; Khoury JD; Medeiros LJ; Hu S Blood Cancer J; 2024 Jan; 14(1):19. PubMed ID: 38272888 [No Abstract] [Full Text] [Related]
109. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. Erba HP Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137 [TBL] [Abstract][Full Text] [Related]
110. New treatment for acute myelogenous leukemia. DiNardo CD; Cortes JE Expert Opin Pharmacother; 2015 Jan; 16(1):95-106. PubMed ID: 25480777 [TBL] [Abstract][Full Text] [Related]
111. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Hunger SP; Mullighan CG Blood; 2015 Jun; 125(26):3977-87. PubMed ID: 25999453 [TBL] [Abstract][Full Text] [Related]
112. The relationship between clinical feature, complex immunophenotype, chromosome karyotype, and outcome of patients with acute myeloid leukemia in China. Ding B; Zhou L; Jiang X; Li X; Zhong Q; Wang Z; Yi Z; Zheng Z; Yin C; Cao R; Liao L; Meng F Dis Markers; 2015; 2015():382186. PubMed ID: 25944974 [TBL] [Abstract][Full Text] [Related]
113. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Dabaja BS; Vanderplas AM; Crosby-Thompson AL; Abel GA; Czuczman MS; Friedberg JW; Gordon LI; Kaminski M; Niland J; Millenson M; Nademanee AP; Zelenetz A; LaCasce AS; Rodriguez MA Cancer; 2015 Apr; 121(7):1032-9. PubMed ID: 25492236 [TBL] [Abstract][Full Text] [Related]
114. A cytogenetic model predicts relapse risk and survival in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation in morphologic complete remission. Rashidi A; Cashen AF Leuk Res; 2015 Jan; 39(1):77-81. PubMed ID: 25481050 [TBL] [Abstract][Full Text] [Related]
115. Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review. Ma Y; Wu Y; Shen Z; Zhang X; Zeng D; Kong P Clin Transplant; 2015 Feb; 29(2):149-60. PubMed ID: 25430616 [TBL] [Abstract][Full Text] [Related]
116. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459 [TBL] [Abstract][Full Text] [Related]
117. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Neuendorff NR; Burmeister T; Dörken B; Westermann J Ann Hematol; 2016 Aug; 95(8):1211-21. PubMed ID: 27297971 [TBL] [Abstract][Full Text] [Related]
119. A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects. Wang Z; Liu T; Liu W; Gao X; Wan L; Qiu S; Song Y; Gu R; Tian Z; Wang M; Wang J; Mi Y; Wei S Cancer Gene Ther; 2023 Nov; 30(11):1471-1484. PubMed ID: 37550570 [TBL] [Abstract][Full Text] [Related]